- Home
- Results news
- Sanofi India
- Q2 FY27 results
Sanofi India Q2 FY27 results: net profit up 53.6% to ₹116.70 crore, revenue up 3.4%
Sanofi India Limited reported standalone revenue of ₹491.70 crore and a net profit of ₹116.70 crore for Q2 FY27. Revenue rose 3.4% from the year-ago quarter, while EBITDA rose 20.1% and the EBITDA margin expanded to 32.8%.
Key points
- Q2 FY27 standalone revenue was ₹491.70 crore, up 3.4% from Q2 FY26 and 12.3% from Q1 FY27.
- EBITDA was ₹161.20 crore in Q2 FY27, up 20.1% year on year, with the margin at 32.8%.
- Net profit was ₹116.70 crore in Q2 FY27, up 53.6% from Q2 FY26 and 39.8% from Q1 FY27.
- Basic EPS was ₹50.67, compared with ₹32.99 in Q2 FY26 and ₹36.26 in Q1 FY27.
- For H1 FY27, revenue was ₹1,401.70 crore, while PAT was ₹302.80 crore.
How did Sanofi India perform in Q2 FY27?
Sanofi India reported standalone revenue of ₹491.70 crore for Q2 FY27, compared with ₹475.40 crore in Q2 FY26 and ₹437.70 crore in Q1 FY27. Revenue rose 3.4% year on year and 12.3% sequentially. Total income was ₹497.20 crore, up from ₹480.30 crore a year ago and ₹443.90 crore in the previous quarter.
EBITDA rose to ₹161.20 crore from ₹134.20 crore in Q2 FY26 and ₹115.30 crore in Q1 FY27. The EBITDA margin was 32.8%, up 4.6 percentage points year on year and 6.5 percentage points from the previous quarter. PBT was ₹157.70 crore, compared with ₹102.30 crore and ₹112.30 crore, respectively.
Net profit was ₹116.70 crore in Q2 FY27, against ₹76 crore in Q2 FY26 and ₹83.50 crore in Q1 FY27. The PAT margin was 23.7%, up 7.7 percentage points year on year and 4.6 percentage points from the previous quarter. Basic EPS was ₹50.67, compared with ₹32.99 and ₹36.26. No consolidated figures were provided in the available information.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 491.70 | 437.70 | 475.40 | +3.4% | +12.3% |
| Other income | 5.50 | 6.20 | 4.90 | +12.2% | −11.3% |
| Total expenses | 339.50 | 331.60 | 350.70 | −3.2% | +2.4% |
| EBITDA | 161.20 | 115.30 | 134.20 | +20.1% | +39.8% |
| EBITDA margin | 32.8% | 26.3% | 28.2% | +4.6 pp | +6.5 pp |
| Profit before tax | 157.70 | 112.30 | 102.30 | +54.2% | +40.4% |
| Tax | 41 | 28.80 | 26.30 | +55.9% | +42.4% |
| Net profit | 116.70 | 83.50 | 76 | +53.6% | +39.8% |
| EPS (₹) | 50.67 | 36.26 | 32.99 | +53.6% | +39.7% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Sanofi India's costs and profit?
Total expenses fell to ₹339.50 crore in Q2 FY27 from ₹350.70 crore in Q2 FY26, a decline of 3.2%. Cost of materials rose to ₹73.60 crore from ₹53.30 crore, but employee cost fell to ₹39.70 crore from ₹41.90 crore, finance costs to ₹0.20 crore from ₹0.40 crore, depreciation to ₹8.80 crore from ₹9.10 crore, and other expenses to ₹52.80 crore from ₹59.40 crore.
Other income rose to ₹5.50 crore from ₹4.90 crore in Q2 FY26. The year-ago quarter included an exceptional charge of ₹27.30 crore, while Q2 FY27 had no exceptional item. Tax was ₹41 crore, up from ₹26.30 crore. The filing attributed gross margin improvement to favourable product mix, a one-off reversal of provisions and disciplined cost management through operational efficiencies.
Against Q1 FY27, total expenses rose to ₹339.50 crore from ₹331.60 crore. Cost of materials increased to ₹73.60 crore from ₹57.30 crore, while employee cost fell to ₹39.70 crore from ₹44.60 crore and other expenses were ₹52.80 crore compared with ₹52.60 crore. Other income declined to ₹5.50 crore from ₹6.20 crore, and tax rose to ₹41 crore from ₹28.80 crore. Both quarters had no exceptional item.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 73.60 | 53.30 | +20.30 | +38.1% |
| Employee cost | 39.70 | 41.90 | −2.20 | −5.3% |
| Finance costs | 0.20 | 0.40 | −0.20 | −50.0% |
| Depreciation | 8.80 | 9.10 | −0.30 | −3.3% |
| Other expenses | 52.80 | 59.40 | −6.60 | −11.1% |
| Total expenses | 339.50 | 350.70 | −11.20 | −3.2% |
| Other income | 5.50 | 4.90 | +0.60 | +12.2% |
| Tax | 41 | 26.30 | +14.70 | +55.9% |
| Exceptional items | none | −27.30 (charge) |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, standalone revenue was ₹1,401.70 crore, down 1.1% from ₹1,417.60 crore in H1 FY26. Total income fell 1.2% to ₹1,417.80 crore from ₹1,434.50 crore. The period ended 30 September 2026 and was unaudited.
PBT rose 12.8% to ₹407.90 crore from ₹361.70 crore in H1 FY26. PAT increased 14.3% to ₹302.80 crore from ₹265.00 crore, while basic EPS rose 14.3% to ₹131.48 from ₹115.06.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 1,402 | 1,418 | −1.1% |
| Profit before tax | 407.90 | 361.70 | +12.8% |
| Net profit | 302.80 | 265 | +14.3% |
| EPS (₹) | 131.48 | 115.06 | +14.3% |
Source: Company's results filing (XBRL).
How has Sanofi India done over the last 8 quarters?
Revenue reached ₹535.90 crore in Q4 FY25, then moved to ₹406.30 crore in Q1 FY26 and ₹419.80 crore in Q3 FY26. It recovered to ₹491.70 crore in Q2 FY27, with revenue rising year on year in each of the last two quarters. PAT bottomed at ₹61.70 crore in Q3 FY26 and rose to ₹116.70 crore in Q2 FY27.
The EBITDA margin bottomed at 21.5% in Q3 FY26, improved to 30.2% in Q4 FY26 and eased to 26.3% in Q1 FY27 before reaching 32.8% in Q2 FY27. Profit also rose year on year in each of the last two quarters. The latest quarter was the highest-margin period in the eight-quarter series.
How did Sanofi India shares react?
The filing appeared after market hours on 29 October 2026. From the price when it appeared, Sanofi India was up 4.5% after five minutes, 2.1% after 15 minutes and 1.1% after 30 minutes. On the reaction day, the stock closed 0.4% below its previous close, while the Pharmaceuticals industry median fell 0.8%.
Past reaction-day moves were mixed: the stock fell 5.3% on 31 July 2025 and rose 4.2% on 14 May 2025. Other results-day moves included a fall of 3.1% on 25 February 2026 and a rise of 1.5% on 27 February 2025.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | +4.5% | |
| 15 minutes | +2.1% | |
| 30 minutes | +1.1% | |
| Reaction day | −0.4% | −0.8% |
| Next day | +4.7% | −0.8% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 4 August 2026 | −2.2% |
| 28 April 2026 | −1.0% |
| 25 February 2026 | −3.1% |
| 29 October 2025 | −0.5% |
| 31 July 2025 | −5.3% |
| 14 May 2025 | +4.2% |
| 27 February 2025 | +1.5% |
| 7 November 2024 | −1.7% |
Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
Sixty other Pharmaceuticals companies had filed for the quarter by 4 November 2026. Their median revenue growth was 19.8%, compared with Sanofi India’s 3.4% growth. Eleven peers grew slower than Sanofi India, while 49 grew faster than the company.
Among the 54 peers for which profit was compared, 38 reported higher profit. The peer figures cover the other Pharmaceuticals companies that had filed by 4 November 2026.
| Sanofi India revenue growth (YoY) | +3.4% |
|---|---|
| Median of 60 other Pharmaceuticals companies | +19.8% |
| Companies with slower revenue growth than Sanofi India | 11 of 60 |
| Companies with faster revenue growth than Sanofi India | 49 of 60 |
| Companies whose net profit rose | 38 of 54 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Sanofi India's revenue in Q2 FY27?
Revenue from operations was ₹491.70 crore, up 3.4% from ₹475.40 crore in Q2 FY26 (standalone).
Did Sanofi India make a profit in Q2 FY27?
Yes. Net profit was ₹116.70 crore, against a net profit of ₹76 crore in Q2 FY26.
What was Sanofi India's EPS in Q2 FY27?
Basic earnings per share were ₹50.67, against ₹32.99 in Q2 FY26.
How did Sanofi India shares react to the Q2 FY27 results?
On the reaction day the stock moved −0.4% from the previous close; the median Pharmaceuticals stock moved −0.8%.
When did Sanofi India announce its Q2 FY27 results?
On 29 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2026; And Declaration And Approval Of Interim Dividend, If Any, For The Financial Year 2026. (BSE, 19 October 2026) · PDF
- Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2026 (BSE, 29 October 2026) · PDF
- Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Thursday, 29Th October 2026 (BSE, 29 October 2026) · PDF
- Announcement under Regulation 30 (LODR)-Press Release / Media Release (BSE, 29 October 2026) · PDF
- Corporate Action-Board approves Dividend (BSE, 29 October 2026) · PDF
- Record Date For Interim Dividend For The Financial Year 2026 (BSE, 29 October 2026) · PDF
- Announcement under Regulation 30 (LODR)-Dividend Updates (BSE, 29 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.